Youth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study
Authors:
- Risa M. WolfRWRisa M. Wolf
- Robin L. GalRGRobin L. Gal
- William TamborlaneWTWilliam Tamborlane
- Michelle Van NameMNMichelle Van Name
- Pediatric Diabetes ConsortiumPCPediatric Diabetes Consortium
- 9 February 2022
- journal article
- research article
- Published by Wiley in Pediatric Diabetes
- Vol. 23 (4) , 439-446
Abstract
Objective Insulin is commonly used to reverse gluco-toxicity in youth with newly diagnosed type 2 diabetes (T2D), but many are subsequently weaned off insulin. We analyzed Pediatric Diabetes Consortium (PDC) data to determine how long glycemic control is maintained after termination of initial insulin treatment. Methods Youth with T2D who had previously been on insulin but were on either an intensive lifestyle intervention alone or metformin alone upon enrollment in the PDC T2D Registry were studied (N=183). The primary outcome was time to treatment failure, defined by need to restart insulin or metformin or another diabetes medication. Data were analyzed using logistic regression to assess risk factors for treatment failure. Results Of the 183 participants studied (mean age 15 years, diabetes duration 1.7 years), 54% experienced treatment failure (median follow-up time 1.7 years). In the subgroup on metformin monotherapy (N=140), 45% subsequently required restart of insulin. Moreover, of participants in the subgroup treated with an intensive lifestyle intervention alone (N=43), 81% restarted insulin or were treated with metformin or other diabetes medication. In both groups, median time to treatment failure was 1.2 years. Higher HbA1c at enrollment was significantly associated with treatment failure (p<0.001). Conclusions Youth with T2D who are initially treated with insulin have a high rate of treatment failure when switched to intensive lifestyle alone or metformin alone. Our data highlight the severe and progressive nature of youth-onset T2D, hence patients should be monitored closely for deteriorating glycemic control after being weaned off insulin.Keywords
Funding Information
- Boehringer Ingelheim
- Novo Nordisk
- Takeda Pharmaceutical Company
This publication has 21 references indexed in Scilit:
- Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and PrioritiesDiabetes Care, 2016
- A cross-sectional view of the current state of treatment of youth with type 2 diabetes in the USA: enrollment data from the Pediatric Diabetes Consortium Type 2 Diabetes RegistryPediatric Diabetes, 2016
- Relationship Between Parental Diabetes and Presentation of Metabolic and Glycemic Function in Youth With Type 2 Diabetes: Baseline Findings From the TODAY TrialDiabetes Care, 2015
- HbA1c After a Short Period of Monotherapy With Metformin Identifies Durable Glycemic Control Among Adolescents With Type 2 DiabetesDiabetes Care, 2015
- Presentation of youth with type 2 diabetes in the Pediatric Diabetes ConsortiumPediatric Diabetes, 2015
- Presentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the TODAY studyPediatric Diabetes, 2015
- Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAYDiabetes Care, 2013
- Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and AdolescentsPediatrics, 2013
- Progressive deterioration of β-cell function in obese youth with type 2 diabetesPediatric Diabetes, 2012
- A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 DiabetesNew England Journal of Medicine, 2012